German pricing squeeze

The Association of Research-based Pharmaceutical Companies (VFA), a trade organization of 40 pharma companies in Germany, has warned that the industry would face losses of more than DM 4 billion ($1.9 billion) a year if programs designed to cut the cost of drugs are implemented, threatening investments in R&D and putting jobs at risk.

In late September, the federal health ministry

Read the full 602 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE